Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
RESEARCH TOOLSreports
Holding KALV?
Track your performance easily
KALV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.21 - $16.88
Previous Close$10.69
Volume272.05K
Average Volume (3M)350.22K
Market Cap
$461.97M
Enterprise Value$293.95M
Total Cash (Recent Filing)$174.27M
Total Debt (Recent Filing)$6.25M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Dec 05, 2024EPS Estimate
-$0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding43,215,472
10 Day Avg. Volume407,254
30 Day Avg. Volume350,220
Standard Deviation0.26
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$29.20Price Target Upside165.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Welcomes New CFO for Future Growth
PremiumPre-Earnings
Is KALV a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical DataSebetralstat's data has already shown that it is as effective as other approved injectable on-demand HAE therapies.
Market OpportunitySebetralstat could fill an unmet need with a compelling efficacy and safety profile combined with the clear desire for convenient oral therapies.
Regulatory ApprovalThe FDA recently accepted sebetralstat's NDA with a PDUFA goal date of June 17, 2025.
Bears Say
CompetitionDeucrictibant is positioned as a potential competitor to sebetralstat in the future.
Market PositionDeucrictibant could position as a potential competitor to sebetralstat in the future.
Stock PerformanceStock has been flattish despite major milestones like phase III success and NDA filing.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.21 and its highest was $16.88 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Dec 05, 2024 which is in 76 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Sep 05, 2024. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$0.915 by $0.045.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -$0.93.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 43,215,473 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.87 in its last earnings report, beating expectations of -$0.915. Following the earnings report the stock price went down -0.387%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds KalVista Pharmaceuticals’s shares valued at 6M.
---
KalVista Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.20 (165.45% Upside)
$29.20 (165.45% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 14.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.08%
12-Months-Change
Fundamentals
Return on Equity
-90.84%
Trailing 12-Months
Asset Growth
24.86%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
KALV Stock 12 Month Forecast
Average Price Target
$29.20
▲(165.45% Upside)
Technical Analysis
Best Analysts Covering KALV
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+6.40%
reiterated a buy rating 15 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +6.40% per trade.
---